Dantrolene is a muscle relaxant used primarily to treat two conditions: malignant hyperthermia, a life-threatening reaction to general anesthesia, and chronic muscle spasticity caused by neurological conditions like multiple sclerosis, spinal cord injuries, stroke, or cerebral palsy. It works differently from other muscle relaxants because it acts directly on muscle cells rather than on the brain or spinal cord.
How Dantrolene Works
Your muscles contract when calcium floods out of an internal storage compartment (called the sarcoplasmic reticulum) into the surrounding cell. Dantrolene blocks the channel responsible for that calcium release. By keeping calcium locked inside the storage compartment, it prevents muscles from contracting as forcefully or as frequently.
The specific channel it targets is called the ryanodine receptor (RyR1). In people susceptible to malignant hyperthermia, a genetic mutation makes this channel “leaky,” allowing calcium to pour out when it shouldn’t. Recent imaging studies have shown that dantrolene binds to a region of the channel far from the actual gate, essentially restricting the channel’s movement and partially reversing the structural defect caused by the mutation. Think of it as tightening a loose valve rather than plugging a hole.
Malignant Hyperthermia
Malignant hyperthermia is the most urgent reason dantrolene exists. It’s a rare but potentially fatal reaction triggered by certain anesthetic gases or the paralytic drug succinylcholine during surgery. In susceptible people, exposure causes uncontrolled muscle contraction, skyrocketing body temperature, a dangerous buildup of acid in the blood, and organ damage. Before dantrolene became available, the condition killed the majority of people who developed it.
When an episode is recognized, dantrolene is given intravenously at a starting dose of 2.5 mg/kg of body weight. Additional doses can follow, up to a suggested upper limit of 10 mg/kg. In very large patients or severe episodes, those higher doses are sometimes necessary. Speed matters enormously: the faster dantrolene reaches the bloodstream, the better the outcome. Every operating room and surgical facility is required to keep a supply on hand.
A newer concentrated formulation called Ryanodex allows a full dose to be mixed in just 5 mL of sterile water per vial, compared to the older version that required 60 mL per vial. That difference saves critical minutes during an emergency, since multiple vials often need to be prepared at once.
Chronic Muscle Spasticity
Outside the operating room, dantrolene is prescribed as an oral capsule for people living with ongoing muscle stiffness and spasms. The FDA-approved conditions include spasticity related to spinal cord injuries, stroke, multiple sclerosis, and cerebral palsy. It can reduce painful tightness, improve range of motion, and make daily activities like dressing or transferring from a wheelchair more manageable.
The dosing ramp-up is gradual. Treatment typically starts at a low dose taken once daily for seven days, then increases every seven days until the medication is taken three to four times a day. This slow approach lets your body adjust and helps identify the lowest effective dose. Because dantrolene reduces the force of all skeletal muscle (not just the stiff ones), some people notice overall weakness as a trade-off for less spasticity. Finding the right balance takes time and close follow-up.
Off-Label Use in Neuroleptic Malignant Syndrome
Dantrolene is also used, though somewhat controversially, to treat neuroleptic malignant syndrome (NMS). This condition resembles malignant hyperthermia but is triggered by antipsychotic medications rather than anesthesia. Symptoms include severe muscle rigidity, high fever, altered mental status, and unstable blood pressure and heart rate.
Because the muscle rigidity and heat generation in NMS involve similar calcium-driven processes, dantrolene can help by directly relaxing skeletal muscle. Evidence suggests it shortens the duration of illness, though the response isn’t immediate. Fever and rigidity typically improve over a mean of about 1.7 days. Most patients who receive it for NMS respond to oral doses of 400 mg per day or less. Its role remains debated because NMS is rare enough that large controlled trials don’t exist, but it remains a commonly used option when rigidity and fever are prominent.
Liver Risk With Long-Term Use
The most serious concern with oral dantrolene is liver damage. The drug carries a black box warning from the FDA, the strongest safety alert a medication can receive, specifically for hepatotoxicity. Symptomatic liver inflammation, including fatal cases, has been reported.
The risk is dose-dependent. Liver injury is much less common in people taking up to 400 mg per day, but the rate climbs significantly at 800 mg per day or higher. Even short courses at those elevated doses markedly increase the danger. For this reason, liver function blood tests should be done before starting treatment to establish a baseline, then repeated at regular intervals throughout therapy. If blood tests show rising liver enzymes, the medication is typically stopped.
This liver risk is specific to long-term oral use. The intravenous form used in emergencies can also affect liver enzymes, but it doesn’t carry the same black box warning because it’s given as a short, one-time intervention rather than daily over weeks or months.
Interaction With Certain Heart Medications
Dantrolene interacts dangerously with two specific calcium channel blockers: verapamil and diltiazem. Combining them has been linked to hyperkalemia (dangerously high potassium levels), severe drops in heart function, and slowed heart rate. These effects were documented in both case reports and animal studies, particularly at higher dantrolene doses.
That said, if someone on chronic verapamil or diltiazem develops malignant hyperthermia, dantrolene should never be withheld. The risk of untreated malignant hyperthermia far outweighs the interaction risk. A different class of calcium channel blockers, the dihydropyridines (which includes common blood pressure medications like amlodipine and nifedipine), does not appear to interact with dantrolene and does not need to be stopped.
Common Side Effects
The most frequently reported side effects with oral dantrolene are drowsiness, dizziness, weakness, and fatigue. Diarrhea is also common, sometimes severe enough to require stopping the drug. Because dantrolene relaxes all skeletal muscle, generalized weakness can interfere with walking or grip strength, particularly in people who rely on some degree of spasticity to stand or transfer. Nausea and sensitivity to sunlight are also reported.
With intravenous use during emergencies, muscle weakness and phlebitis (irritation at the injection site) are the most notable effects. These are generally considered acceptable given that the alternative, an untreated malignant hyperthermia crisis, is far worse.